Analysts Offer Predictions for Endo International PLC’s FY2020 Earnings (NASDAQ:ENDP)

Endo International PLC (NASDAQ:ENDP) (TSE:ENL) – Stock analysts at SunTrust Banks lifted their FY2020 earnings estimates for Endo International in a research report issued on Monday, July 15th. SunTrust Banks analyst G. Gilbert now forecasts that the company will post earnings per share of $2.53 for the year, up from their previous forecast of $2.52. SunTrust Banks also issued estimates for Endo International’s FY2021 earnings at $2.27 EPS and FY2023 earnings at $1.59 EPS.

A number of other research firms have also commented on ENDP. BidaskClub raised WhiteHorse Finance from a “sell” rating to a “hold” rating in a research note on Thursday. Royal Bank of Canada lowered Amneal Pharmaceuticals from an “outperform” rating to a “sector perform” rating and reduced their price objective for the stock from $11.00 to $6.00 in a research note on Thursday, July 11th. Gabelli reissued a “hold” rating on shares of Endo International in a research note on Wednesday, March 27th. JPMorgan Chase & Co. boosted their price objective on Vermilion Energy from C$42.00 to C$43.00 in a research note on Monday, May 13th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $130.00 price objective (up previously from $116.00) on shares of Zoetis in a research note on Wednesday, June 12th. Four analysts have rated the stock with a sell rating, fourteen have issued a hold rating and three have given a buy rating to the company’s stock. Endo International currently has a consensus rating of “Hold” and an average price target of $10.73.

Shares of ENDP stock opened at $3.34 on Wednesday. The company has a fifty day moving average of $4.32. The firm has a market cap of $834.61 million, a price-to-earnings ratio of 1.16 and a beta of 1.15. Endo International has a one year low of $3.24 and a one year high of $18.50.

Endo International (NASDAQ:ENDP) (TSE:ENL) last announced its quarterly earnings results on Thursday, May 9th. The company reported $0.53 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.42 by $0.11. The business had revenue of $720.00 million for the quarter, compared to analyst estimates of $692.31 million. Endo International had a negative return on equity of 199.18% and a negative net margin of 18.35%. Endo International’s quarterly revenue was up 2.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.67 EPS.

In other news, Director Roger H. Kimmel sold 34,951 shares of the company’s stock in a transaction on Monday, June 17th. The stock was sold at an average price of $3.93, for a total transaction of $137,357.43. Following the transaction, the director now owns 148,309 shares of the company’s stock, valued at $582,854.37. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 0.80% of the company’s stock.

Several institutional investors and hedge funds have recently modified their holdings of ENDP. Signition LP acquired a new position in shares of Endo International during the first quarter valued at $139,000. Neuburgh Advisers LLC lifted its stake in shares of Endo International by 13.9% during the fourth quarter. Neuburgh Advisers LLC now owns 24,860 shares of the company’s stock valued at $181,000 after acquiring an additional 3,036 shares during the period. Factorial Partners LLC acquired a new position in shares of Endo International during the first quarter valued at $193,000. First Quadrant L P CA lifted its stake in shares of Endo International by 94.7% during the first quarter. First Quadrant L P CA now owns 24,513 shares of the company’s stock valued at $197,000 after acquiring an additional 11,926 shares during the period. Finally, Nisa Investment Advisors LLC lifted its stake in shares of Endo International by 61.4% during the first quarter. Nisa Investment Advisors LLC now owns 42,256 shares of the company’s stock valued at $339,000 after acquiring an additional 16,077 shares during the period. 93.59% of the stock is currently owned by institutional investors and hedge funds.

About Endo International

Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals.

Further Reading: Understanding Market Liquidity

Earnings History and Estimates for Endo International (NASDAQ:ENDP)

Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.